Saturday 17 October 2026
Export FTH’s income statement to Excel — free account
Faeth Therapeutics, Inc.
In the quarter to June 2026, EPS grew 27.4% and free cash flow fell 174.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
18.79
1.81
−8.79%
Follow FTH
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
5.81 | 5.06 | 14.39 | 19.69 |
Net Debt/EBITDA |
5.20 | 4.30 | 1.19 | 10.15 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.78 | 0.82 | 0.06 | 0.98 | |
Capex/Depreciation |
0.00 | 0.00 | (0.20) | 0.00 | |
Interest Coverage |
(808.50) | (190.65) | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(2.84) | (3.06) | (8.29) | (2.78) | |
Cash per Share |
19.86 | 16.80 | 156.58 | 33.04 | |
Shareholders Equity per Share |
18.25 | 14.74 | (106.00) | 30.65 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
18.25 | 14.74 | (106.00) | 30.65 | |
Free Cash Flow |
(3.59) | (3.86) | (10.74) | (15.67) | |
Working Capital |
21.35 | 17.26 | 190.04 | 179.08 | |
Capital Expenditures |
0.00 | 0.00 | (0.01) | 0.00 | |
Net Current Asset Value |
21.20 | 17.20 | (138.43) | 172.31 | |
| Other line items | |||||
Quick Ratio |
5.65 | 4.98 | 14.29 | 19.46 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.84) | (3.06) | (8.29) | (2.78) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.54 | 1.36 | 5.67 | 4.35 | |
Average Assets |
40.42 | 34.13 | 121.83 | 110.54 | |
Average Common Equity |
34.39 | 28.49 | (52.65) | 100.14 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates